论文部分内容阅读
The interest in Amorphous Solid Dispersions (ASDs) as a means of improving solubility of Active Pharmaceutical Ingredients (APIs) is still strong as highlighted by many recently approved market products.Unlike crystalline APIs which solubilities and dissolution rates are reduced due to high lattice energy barriers, the amorphous phase has high apparent solubility, good dissolution rates and bioavailability.In an amorphous solid dispersion the API is at the molecular level dispersed in a polymer matrix.The mobility of the API molecules must be low enough to ensure that it will be unlikely that crystallization nuclei are formed.Making use of the amorphous phase of your drug rather than crystalline forms could shift your drug from a class 2 (or 4) into a class 1 (or 3) drug according to the biopharmaceutical classification system.In this presentation, the techniques for making ASD by spray drying and hot melt extrusion will be thoroughly discussed.